Generalized pustular psoriasis (GPP) is a rare, severe inflammatory skin disease defined by sudden widespread eruptions of sterile pus-filled bumps across large areas of the body, often on top of red, swollen skin. It is not simply a bad case of the common plaque psoriasis most people picture when they hear “psoriasis.” GPP is increasingly understood as a distinct condition driven by a different arm of the immune system, and its flares can become life-threatening, with reported mortality rates between 2 and 16 percent when complications arise.1PubMed Central. Generalized Pustular Psoriasis: A Review on Clinical Characteristics, Diagnosis, and Treatment The good news is that the first targeted therapy specifically approved for GPP flares arrived in 2022, and the science behind it is moving fast.
What Happens During a Flare
A GPP flare can come on within hours or days. The skin turns fiery red and swollen, then erupts with hundreds or thousands of tiny pustules, often merging into larger sheets. Despite their alarming appearance, these pustules are sterile — they are filled with white blood cells (neutrophils), not bacteria. Beyond the skin, flares are usually accompanied by high fever, extreme fatigue, and a general feeling of being seriously unwell.2PubMed Central. Clinical Course and Characteristics of Generalized Pustular Psoriasis Skin pain, burning, itching, and scaling typically follow as the pustules dry and the skin peels.
What makes GPP genuinely dangerous is what it can do beyond the skin. Flares may trigger organ-level complications including sepsis (even without bacterial infection, because the body’s inflammatory response spirals), kidney failure, liver dysfunction, respiratory failure, and heart failure.3PubMed Central. Generalized Pustular Psoriasis: A Review on Clinical Characteristics, Diagnosis, and Treatment Blood tests during a flare commonly show a surge in neutrophils, elevated markers of inflammation, abnormal liver enzymes, and low calcium and albumin levels. Extracutaneous manifestations like joint inflammation (arthritis), eye inflammation (uveitis), and bile-duct inflammation can also appear.4PubMed Central. Clinical Course and Characteristics of Generalized Pustular Psoriasis The unpredictability is part of the burden: flare duration and the intervals between episodes vary enormously from person to person, with no reliable way to predict when the next one will hit.
How GPP Differs From Plaque Psoriasis
Most people with psoriasis have plaque psoriasis — thick, scaly patches that wax and wane over years. GPP looks and behaves quite differently. The hallmark is the sudden, widespread pustular eruption rather than a slow buildup of plaques. Some patients with GPP also have a history of plaque psoriasis, but many do not, and the two conditions can exist independently. At a biological level, plaque psoriasis is driven mainly by the adaptive immune system, involving T cells and pathways centered on molecules like IL-17 and IL-23. GPP, by contrast, is increasingly recognized as an autoinflammatory disease, meaning the innate immune system — the body’s rapid, less specific first-responder arm — is the primary driver.5PubMed Central. Pathophysiology of generalized pustular psoriasis
That distinction matters because it changes which treatments work. A therapy that controls plaque psoriasis by targeting T-cell-driven inflammation may do little to stop a GPP flare fueled by a different set of signals. Research comparing the molecular profiles of GPP and plaque psoriasis skin has confirmed this split: GPP lesions show higher levels of IL-1 and IL-36 and lower levels of IL-17A and interferon-gamma compared with plaque psoriasis lesions.6Journal of Allergy and Clinical Immunology. The transcriptome of generalized pustular psoriasis reveals increased inflammation and skewing of the IL-1/36 pathway In practical terms, the two diseases overlap enough to confuse diagnosis but diverge enough to require different management strategies.
The IL-36 Pathway and Why It Matters
The core engine of GPP centers on a signaling molecule called IL-36. In healthy skin, IL-36 helps recruit immune cells to fight off infections and then gets switched off by a natural brake — an antagonist protein encoded by a gene called IL36RN. In many GPP patients, that brake is defective. When IL-36 signaling goes unchecked, it activates a cascade that churns out inflammatory signals including CXCL8 (which pulls neutrophils into the skin by the millions), TNF-alpha, IL-1, and IL-23.7PubMed Central. Role of Interleukin 36 in Generalised Pustular Psoriasis and Beyond The result is the massive neutrophil accumulation that forms visible pustules, the systemic fever, and the organ stress seen in severe flares.
Understanding that IL-36 sits at the center of GPP pathology is what led directly to the development of spesolimab, the first drug designed to block the IL-36 receptor specifically. But not all GPP is purely an IL-36 story — other inflammatory pathways contribute, and not every patient carries an IL36RN mutation. The disease is best understood as a final common pathway where multiple upstream triggers funnel into the same explosive neutrophilic response.
Genetics Behind GPP
The landmark genetic discovery in GPP came when researchers identified mutations in IL36RN as a cause of the disease. IL36RN encodes the antagonist that normally counteracts IL-36 signaling. Loss-of-function mutations in this gene leave the inflammatory pathway unopposed, essentially removing the “off switch.”8PubMed Central. Mutations in IL36RN/IL1F5 Are Associated with the Severe Episodic Inflammatory Skin Disease Known as Generalized Pustular Psoriasis This condition has been called DITRA (deficiency of the IL-36 receptor antagonist), and it tends to present early in life with particularly severe flares.
IL36RN is the best-studied genetic contributor, but it is not the only one. Variants in CARD14, AP1S3, and MPO have also been linked to GPP, either as direct causes or as contributing genetic factors.9PubMed Central. An update on genetic basis of generalized pustular psoriasis More recently, variants in the MEFV gene — already known for its role in familial Mediterranean fever — have been flagged as a risk factor in pediatric GPP.10PubMed. Pediatric Patient With Generalized Pustular Psoriasis With MEFV Gene Variant: Successful Treatment With Adalimumab Still, a substantial proportion of GPP patients carry none of these known mutations, so clearly there is more genetic territory to map. Genetic testing is becoming more common in clinical practice, particularly in early-onset cases, but a negative result does not rule out the diagnosis.
What Triggers a Flare
Even in someone genetically predisposed, GPP flares are often kicked off by an identifiable trigger. The most well-documented culprit is medication, with corticosteroid withdrawal topping the list — a cruel irony, since steroids are sometimes prescribed for inflammatory skin conditions. Infections can set off flares, likely by activating innate immune receptors that feed into the same IL-36 pathway. Pregnancy is another recognized trigger. Low calcium levels, stress, and sun exposure have also been implicated.11PubMed. Update on the aetiology and mechanisms of generalized pustular psoriasis
The calcium connection is worth noting because low calcium and vitamin D levels can alter how skin cells grow and differentiate, potentially priming the skin for a pustular reaction. In practice, many patients find that flares seem to come out of nowhere, and the trigger is never identified. The unpredictability is a major source of anxiety, and clinicians generally advise avoiding rapid steroid withdrawal and treating infections promptly as the most actionable preventive steps.
GPP in Pregnancy
When GPP occurs during pregnancy, it has historically been called impetigo herpetiformis — a misleading name since it has nothing to do with herpes or impetigo. It is now recognized as a form of GPP that is triggered or worsened by the hormonal and metabolic changes of pregnancy, most commonly appearing in the third trimester.12PubMed Central. Impetigo Herpetiformis: Review of Pathogenesis, Complication, and Treatment The condition typically resolves quickly after delivery, but the risk is not only to the mother. Pregnancy-associated GPP can cause placental insufficiency, fetal abnormalities, stillbirth, and early neonatal death, making close monitoring of both mother and fetus essential.13PubMed. Generalized Pustular Psoriasis in Pregnancy: Current and Future Treatments
A concerning pattern is that recurrence in subsequent pregnancies tends to start earlier and be more severe.14PubMed. Generalized Pustular Psoriasis in Pregnancy: Current and Future Treatments Treatment options are constrained by fetal safety concerns — many of the systemic drugs used for GPP carry teratogenic risks — so management is a balancing act between controlling the mother’s disease and protecting the developing baby.
GPP in Children
Pediatric GPP is rare even by GPP standards and is considered a potentially life-threatening variant of childhood psoriasis.15PubMed. Pediatric Patient With Generalized Pustular Psoriasis With MEFV Gene Variant: Successful Treatment With Adalimumab Children who develop GPP early in life are more likely to carry identifiable mutations, particularly in IL36RN. A case report of a three-year-old with confirmed IL36RN mutation illustrates how genetic testing can help clarify the diagnosis and inform treatment decisions in very young patients.16PubMed Central. Generalized pustular psoriasis in a toddler with IL36RN mutation: a case report The challenge in pediatric GPP is that most drugs used to treat the adult form have limited safety and efficacy data in children, so treatment often relies on case-by-case decision-making.
Who Gets GPP and How Common Is It
GPP is genuinely rare, but pinning down its exact prevalence is harder than it sounds. Different countries use different diagnostic definitions, and some studies lump GPP together with palmoplantar pustulosis (a related but distinct condition limited to the hands and feet), which inflates the numbers.17PubMed Central. The Prevalence and Disease Characteristics of Generalized Pustular Psoriasis With those caveats, the available data suggest a prevalence in the range of roughly 8 to 39 per 100,000 adults in Germany and around 21 to 33 per million in England, depending on the year studied.18PubMed Central. Epidemiology and Health Care of Generalized Pustular Psoriasis in Germany – Methodology and Outcomes of Claims Data Analysis19PubMed. Incidence, prevalence, and life expectancy of patients with generalised pustular psoriasis in England: a population-based cohort study exploring ethnic and sex variations
A few demographic patterns are consistent across datasets. GPP is more common in women than men, with one English cohort finding that about 63 percent of identified patients were female. Prevalence increases with age, with a mean age at onset around 51 years, though early-onset cases — often linked to genetic mutations — do occur. There also appear to be ethnic differences: Asian populations show higher rates than White populations, and onset tends to occur earlier in Asian patients.20PubMed. Incidence, prevalence, and life expectancy of patients with generalised pustular psoriasis in England: a population-based cohort study exploring ethnic and sex variations Incidence in England appeared relatively stable until 2016 and then trended upward, though it is unclear how much of this reflects true increases versus better recognition and coding of the disease.
Getting the Diagnosis Right
GPP is defined by widespread sterile superficial pustules, with or without systemic inflammation.21PubMed Central. Diagnosis of Generalized Pustular Psoriasis That definition sounds straightforward, but in practice it is easy to confuse GPP with other conditions that produce widespread pustules. The most common mimic is acute generalized exanthematous pustulosis (AGEP), a drug reaction that can look almost identical to GPP at first glance. Skin biopsy helps distinguish them: AGEP tends to show eosinophils and dying skin cells (necrotic keratinocytes) in the tissue, while GPP does not. GPP also features dilated, tortuous blood vessels in the skin that AGEP lacks.22PubMed. The histopathological spectrum of acute generalized exanthematous pustulosis (AGEP) and its differentiation from generalized pustular psoriasis The distinction matters because AGEP usually resolves on its own once the offending drug is stopped, while GPP requires active treatment and carries a very different long-term outlook.
There is no single blood test that confirms GPP. Diagnosis relies on the combination of clinical appearance, skin biopsy, laboratory findings (elevated inflammatory markers, neutrophilia, low calcium), and the exclusion of mimics. Research into serum biomarkers has found that levels of certain cytokines — particularly IL-10 and IL-22 — track with disease severity and drop in parallel with successful treatment, suggesting they could become useful for monitoring flare activity over time.23PubMed Central. Serum cytokines correlated with the disease severity of generalized pustular psoriasis
Treatment Landscape
For decades, treatment options for GPP were borrowed from plaque psoriasis and supported mostly by small case series rather than rigorous trials. The conventional first-line medications include acitretin (a retinoid), cyclosporine, methotrexate, and infliximab (a TNF-blocker).24PubMed. Review of treatments for generalized pustular psoriasis These drugs can control flares in many patients, but the evidence behind them is thin — largely case reports and open-label studies with small numbers.25PubMed Central. Treatment Options and Goals for Patients with Generalized Pustular Psoriasis Biologics targeting IL-17 (ixekizumab, secukinumab, brodalumab) and IL-23 (guselkumab) have shown efficacy in individual cases and small studies, expanding the toolkit.26PubMed. Review of treatments for generalized pustular psoriasis
The breakthrough came with spesolimab, a monoclonal antibody that blocks the IL-36 receptor — directly targeting the pathway now understood to sit at the center of GPP. In a randomized, placebo-controlled trial published in the New England Journal of Medicine, about 54 percent of patients receiving spesolimab had complete clearance of pustules within one week, compared with 6 percent on placebo. Roughly 43 percent achieved a near-clear or clear overall skin score by week one, versus 11 percent on placebo.27PubMed. Trial of Spesolimab for Generalized Pustular Psoriasis These results were striking enough to earn spesolimab approval for GPP flares in multiple countries. It represented a genuine shift — the first time a treatment had been developed and tested specifically for this disease rather than repurposed from plaque psoriasis.
Living With GPP
The day-to-day burden of GPP goes well beyond the flares themselves. Compared with plaque psoriasis, people with GPP report significantly worse quality of life across essentially every measure studied. Pain and itching top the list, with about 87 percent of GPP patients reporting their skin as itchy or painful.28PubMed Central. Health-related quality of life in patients with generalized pustular psoriasis – a Swedish register study Fatigue is pervasive and often rated as more severe than in plaque psoriasis. Anxiety and depression are also more common: in one U.S. registry, about 38 percent of GPP patients reported anxiety or depression, compared with 26 percent of those with plaque psoriasis.29PubMed Central. The Disease Burden of Generalized Pustular Psoriasis: Real-World Evidence From CorEvitas’ Psoriasis Registry Systematic reviews have confirmed that people with GPP consistently report a greater impact on quality of life than those with plaque psoriasis, with higher severity for itch, pain, and fatigue specifically.30PubMed. Health-related quality of life in patients with generalized pustular psoriasis: A systematic literature review
Part of this burden is the treatment itself. GPP patients tend to cycle through more systemic medications than plaque psoriasis patients, with about twice the proportion having tried two or more systemic therapies.31PubMed Central. The Disease Burden of Generalized Pustular Psoriasis: Real-World Evidence From CorEvitas’ Psoriasis Registry Each switch carries its own side effects, monitoring requirements, and period of uncertainty. The unpredictable flare-relapse cycle adds a psychological toll that is hard to capture in quality-of-life questionnaires — the constant vigilance for the next eruption.
Healthcare Costs and Hospitalizations
GPP’s severity translates directly into higher healthcare utilization and costs. A Canadian population-based study found that over a ten-year period, patients with GPP incurred mean medical costs roughly ten times higher than those with plaque psoriasis. Over a three-year window following diagnosis, the difference was similarly stark. Inpatient and emergency-department mortality was also significantly higher in the GPP group — about 5 percent in the three years after diagnosis, compared with roughly 2 percent for plaque psoriasis.32PubMed Central. The burden associated with generalized pustular psoriasis: A Canadian population-based study of inpatient care, emergency departments, and hospital- or community-based outpatient clinics These figures reflect the reality that GPP flares frequently require hospitalization, sometimes in intensive-care settings, and that the long-term complication profile is more serious than for more common forms of psoriasis.
Monitoring Between Flares
Because GPP flares can unpredictably damage organs, routine monitoring between episodes is part of managing the disease. Standard blood work — complete blood counts, liver and kidney function, calcium, albumin, and markers of inflammation like C-reactive protein — helps detect subclinical flare activity. Research into more targeted biomarkers has shown that serum levels of certain cytokines correlate with disease severity and treatment response. Among the most promising are IL-8, CXCL1, IL-10, and IL-22. IL-10 and IL-22 in particular dropped reliably after effective treatment, tracking closely with clinical improvement.33PubMed Central. Serum cytokines correlated with the disease severity of generalized pustular psoriasis These are not yet standard clinical tests, but they point toward a future where blood draws could supplement visual assessment in deciding whether a treatment is working or a flare is brewing.
For patients, the practical takeaway is that GPP management is not just about putting out fires when flares erupt. Ongoing engagement with a dermatologist, regular lab work, and prompt attention to new symptoms — joint pain, eye redness, persistent fever — can catch complications before they become emergencies. The emergence of targeted therapies like spesolimab, along with a growing pipeline of IL-36-directed treatments, gives reason for cautious optimism that the cycle of unpredictable, frightening flares may eventually become something closer to a manageable chronic condition.